Please login to the form below

Not currently logged in
Email:
Password:

Redx Pharma appoints new chief medical officer

Dr Andrew Saunders joins the UK biotech from Lytix Biopharma

Dr Andrew SaundersDrug discovery and development group Redx Pharma has appointed Dr Andrew Saunders as its chief medical officer (CMO), a role that will see him work with the R&D team fronting the clinical development of the company’s lead candidate.

Dr Saunders has worked in the oncology field for over 25 years and has experience in all aspects of the clinical development of oncology drugs.

He joins the UK biotech from Lytix Biopharma, a Norweigan immuno-oncology biotech, where he also served as CMO.

During his career, Dr Saunders has held several roles for both pharma and biotech companies, including Genzyme - now part of Sanofi, Roche, and Eli Lilly.

Ian Ross, chairman of Redx Pharma, said: “Dr Saunders brings a wealth of relevant experience and expertise in the clinical development of oncology drugs, which will be invaluable as the company transforms into a clinical stage company with the anticipated commencement of the first phase I study on lead compound RXC004.”

25th January 2018

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...
How To Tell A Better Silent Story
They say a picture's worth 1,000 words, which is incredibly helpful when telling a silent story....
Main image1
Global leaders in digital channels
Exploring why UK field teams are global leaders in digital channels is key to better understanding the changes in omnichannel engagement...